CompletedNCT01082289
Digoxin and lurasidone interaction in schizophrenia
About this title
Read the official source — NCT01082289Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Culver CitySee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateSeptember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01082289
- Official title
Show the full official title
A Phase 1, Open-Label, Drug-Drug Interaction Study to Determine the Effect of Repeated Dose Lurasidone 120 mg Administration on the Pharmacokinetics of Orally Administered Digoxin 0.25 mg in Patients With Schizophrenia or Schizoaffective Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Culver City
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
